<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02979587</url>
  </required_header>
  <id_info>
    <org_study_id>MDT16004CON001</org_study_id>
    <nct_id>NCT02979587</nct_id>
  </id_info>
  <brief_title>The Medtronic Harmony™ Transcatheter Pulmonary Valve Clinical Study</brief_title>
  <official_title>The Medtronic Harmony™ Transcatheter Pulmonary Valve Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Heart Valves</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Cardiovascular</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to further evaluate the safety and effectiveness of the Harmony™
      TPV system.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The continued clinical experience addendum is a prospective, multi-center, non-randomized,
      interventional study to evaluate the safety and effectiveness of the Harmony TPV system. All
      implanted subjects will receive the Harmony TPV 22 or Harmony mTPV 25 device. This phase
      allows up to 45 subjects implanted with TPV 22 in the United States and Canada, and up to 84
      subjects implanted with mTPV 25 in the United States.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2017</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Freedom from procedure- or device-related mortality at 30 days.</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of subjects with acceptable hemodynamic function composite at 6 months.</measure>
    <time_frame>6 months</time_frame>
    <description>Defined as:
Mean RVOT gradient as measured by continuous‐wave Doppler ≤40 mmHg ‐AND‐
Pulmonary regurgitant fraction as measured by magnetic resonance imaging &lt;20%</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Technical success at exit from catheterization lab/operating room (OR)</measure>
    <time_frame>At exit from catheterization lab/operating room (OR)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device Success out to 5 years</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural Success at 30 days</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from TPV Dysfunction out to 5 years</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of safety</measure>
    <time_frame>5 years</time_frame>
    <description>All procedure-related serious adverse events. All device-related serious adverse events. Death (all-cause, procedural, and device-related).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterization of quality of life scores out to 5 years</measure>
    <time_frame>5 years</time_frame>
    <description>As assessed via the SF-36 QOL form.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterization of right ventricle remodeling following TPV implant</measure>
    <time_frame>5 years</time_frame>
    <description>As assessed via cardiac magnetic resonance imaging</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">184</enrollment>
  <condition>Congenital Heart Disease</condition>
  <condition>Tetrology of Fallot</condition>
  <condition>RVOT Anomaly</condition>
  <condition>Pulmonary Regurgitation</condition>
  <arm_group>
    <arm_group_label>Harmony TPV System</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Intervention Device: Harmony Transcatheter Pulmonary Valves and Delivery Systems</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Harmony TPV System</intervention_name>
    <description>The Harmony™ TPV (Model NTPV0022) is comprised of a 22mm porcine pericardium valve, sewn to a polyester-covered nitinol frame.
The Harmony TPV 25 and mTPV 25 (Model HTPV254952 and HTPV254252, respectively) is comprised of a 25mm porcine pericardium valve, sewn to a polyester covered asymmetrical hourglass nitinol frame with larger diameter inflow and outflow as well as shorter length compared to TPV 22 (Harmony TPV 25 Model HTPV254952 is not applicable for Continued Clinical Experience).
The Harmony Delivery System (DS) for the TPV 22, TPV 25, and mTPV 25 (NTPVDS0022 and HTPVDS0025) are all 25 Fr delivery systems using a coil loading catheter.</description>
    <arm_group_label>Harmony TPV System</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject has severe pulmonary regurgitation as assessed via echocardiography or CMR
             determined PR fraction &gt;/= 30%

          -  Subject has clinical indication for surgical placement of an RV-PA conduit or
             bioprosthetic pulmonary valve

          -  Subject is willing to consent to participate

        Exclusion Criteria:

          -  Patients with right ventricular outflow tract obstruction (RVOTO) lesions surgically
             treated with an RV-to-PA conduit implant

          -  RVOT anatomy or morphology that is unfavorable for device anchoring

          -  Positive pregnancy test

          -  Life expectancy of less than 1 year
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John P Cheatham, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nationwide Children's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stephanie Salisbury</last_name>
    <phone>+16129797251</phone>
    <email>stephanie.salisbury@medtronic.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Harmony Clinical Study Central Email</last_name>
    <email>rs.harmonytpvclinicalstudy@medtronic.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ronald Regan UCLA Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Levi, MD</last_name>
      <phone>310-267-7667</phone>
      <email>dlevi@ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Daniel Levi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Doff McElhinney, MD</last_name>
      <phone>650-736-9364</phone>
      <email>doff@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Doff McElhinney, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeremy Asnes, MD</last_name>
      <phone>203-785-2022</phone>
      <email>jeremy.asnes@yale.edu</email>
    </contact>
    <investigator>
      <last_name>Jeremy Asnes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55902</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John P Cheatham, MD, MSCAI</last_name>
      <phone>614-722-6124</phone>
      <email>John.Cheatham@nationwidechildrens.org</email>
    </contact>
    <contact_backup>
      <last_name>Joanne L Chisolm, MSN, RN</last_name>
      <phone>614-355-5736</phone>
      <email>Joanne.Chisolm@nationwidechildrens.org</email>
    </contact_backup>
    <investigator>
      <last_name>John P Cheatham, MD, MSCAI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Gillespie, MD</last_name>
      <phone>215-590-1790</phone>
      <email>GILLESPIE@email.chop.edu</email>
    </contact>
    <investigator>
      <last_name>Matthew Gillespie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Henri Justino, MD</last_name>
      <phone>832-824-1000</phone>
      <email>hxjustin@texaschildrens.org</email>
    </contact>
    <investigator>
      <last_name>Henri Justino, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Primary Children's Hospital</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84113</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Gray, MD</last_name>
      <phone>801-662-1000</phone>
      <email>Robert.Gray@utah.edu</email>
    </contact>
    <investigator>
      <last_name>Robert Gray, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Jones, MD</last_name>
      <phone>206-987-2000</phone>
      <email>thomas.jones@seattlechildrens.org</email>
    </contact>
    <investigator>
      <last_name>Thomas Jones, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Hospital for Sick Children (SickKids)</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lee Benson, MD</last_name>
      <phone>416-813-6141</phone>
      <email>lee.benson@sickkids.ca</email>
    </contact>
    <investigator>
      <last_name>Lee Benson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Cerebral and Cardiovascular Center</name>
      <address>
        <city>Suita</city>
        <state>Osaka</state>
        <zip>565-8565</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sakakibara Heart Institute</name>
      <address>
        <city>Fuchu</city>
        <state>Tokyo</state>
        <zip>183-0003</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Japan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>November 23, 2016</study_first_submitted>
  <study_first_submitted_qc>November 30, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 1, 2016</study_first_posted>
  <last_update_submitted>June 3, 2020</last_update_submitted>
  <last_update_submitted_qc>June 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Insufficiency</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Pulmonary Valve Insufficiency</mesh_term>
    <mesh_term>Tetralogy of Fallot</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

